Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
E610261-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $238.90 | |
E610261-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $319.90 | |
E610261-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $563.90 | |
E610261-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $839.90 | |
E610261-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,160.90 |
Synonyms | Exarafenib|Exarafenib [INN]|KIN-2787 free base|2VPX8HL8AB|2639957-39-2|UNII-2VPX8HL8AB|(3S)-N-(3-(2-(((2R)-1-Hydroxypropan-2-yl)amino)-6- (morpholin-4-yl)pyridin-4-yl)-4-methylphenyl)-3-(2,2,2- trifluoroethyl)pyrrolidine-1-carboxamide|1-Pyrrolidinecarboxa |
---|---|
Specifications & Purity | ≥98% |
Storage Temp | Protected from light,Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of Raf-1 proto-oncogene; serine/threonine kinase |
Product Description |
Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity.
|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (3S)-N-[3-[2-[[(2R)-1-hydroxypropan-2-yl]amino]-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide |
---|---|
INCHI | InChI=1S/C26H34F3N5O3/c1-17-3-4-21(31-25(36)34-6-5-19(15-34)14-26(27,28)29)13-22(17)20-11-23(30-18(2)16-35)32-24(12-20)33-7-9-37-10-8-33/h3-4,11-13,18-19,35H,5-10,14-16H2,1-2H3,(H,30,32)(H,31,36)/t18-,19+/m1/s1 |
InChi Key | GZMYLSJUNSCMTD-MOPGFXCFSA-N |
Canonical SMILES | Cc1c(cc(cc1)NC(=O)N1CC[C@H](C1)CC(F)(F)F)c1cc(nc(c1)N1CCOCC1)N[C@H](C)CO |
Isomeric SMILES | CC1=C(C=C(C=C1)NC(=O)N2CC[C@H](C2)CC(F)(F)F)C3=CC(=NC(=C3)N4CCOCC4)N[C@H](C)CO |
PubChem CID | 156297592 |
Molecular Weight | 521.58 |
CAS Registry No. | 2639957-39-2 |
---|---|
PubChem CID | 156297592 |
Enter Lot Number to search for COA:
Solubility | DMSO: 50 mg/mL (95.86 mM), Sonication is recommended. |
---|---|
Sensitivity | Light sensitive;Moisture sensitive |